Oncternal Therapeutics, Inc.
(NASDAQ : ONCT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.04%172.250.7%$1088.53m
PFEPfizer Inc. -0.02%42.780.9%$1062.98m
AZNAstraZeneca Plc -0.69%57.241.0%$983.21m
MRKMerck & Co., Inc. -0.13%76.830.7%$651.89m
ABBVAbbVie, Inc. -2.22%116.231.9%$651.72m
BMYBristol-Myers Squibb Co. -0.34%67.921.0%$580.36m
LLYEli Lilly & Co. -0.80%243.361.1%$577.91m
NRXPNRX Pharmaceuticals, Inc. 0.20%15.180.0%$167.78m
NVSNovartis AG 0.25%92.420.2%$154.78m
GSKGlaxoSmithKline Plc 0.13%40.150.2%$154.55m
RGENRepligen Corp. 1.95%245.706.8%$95.53m
VTRSViatris, Inc. -1.54%14.070.0%$86.29m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.06%126.060.0%$85.37m
NVONovo Nordisk A/S 1.32%92.580.1%$81.36m
RPRXRoyalty Pharma Plc -0.13%38.200.2%$73.90m

Company Profile

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Cirmtuzumab, TK216, and ROR1 CAR-T. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.